Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label extension study of fostamatinib for persistent/chronic immune thrombocytopenic purpura
NL-OMON42301Phase 3Active, not recruiting
- Sponsor
- Syneos Health
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of fostamatinib in immune thrombocytopenia (ITP) (2 arms), sponsored by Syneos Health. Primary endpoints: Long-term safety of fostamatinib, Stable platelet count response - Version 1 and 1 more. Started Jul 2015; status: active, not recruiting.
02
Drugs
fostamatinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON42301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42301.